We use cookies to make this site as useful as possible. By continuing browsing we assume that you agree to accept cookies in accordance with our cookie policy.
To find out more or to change your cookie settings at any time, see our cookie policy. OK

  • About
  • Careers
  • Select Dechra business
    • Dechra Pharmaceuticals PLC
    • Dechra Manufacturing
  • Sign in
  • Select country
    • Danmark
    • Suomi
    • France
    • Deutschland
    • Österreich
    • Nederland
    • Norge
    • Ireland
    • Italia
    • España
    • Portugal
    • Sverige
    • United Kingdom
    • België
    • USA
    • Canada
    • Polska
    • Hrvatska
    • Bosna i Hercegovina
    • Slovenija
    • Australia
    • México
    • Global
    • By clicking a flag you will be leaving this country website to access another site in the Dechra group not applicable to your territory and which may have different legislation
Dechra Veterinary Products
Your materials (0)
  • Products
  • Therapy Areas
  • Academy
  • News
  • Events
  • Support Materials
  • Contact
  • Your materials (0)
  • You are here:
  • Home
  • / News
  • Back
  • You are here:
  • News

News

Dechra Veterinary Products launches Europe’s first transdermal ointment for body weight gain in cats

01 March 2021

Dechra Veterinary Products are pleased to announce the launch of Mirataz. Mirataz contains mirtazapine and is the first and only licensed veterinary transdermal ointment for body weight gain in cats experiencing poor appetite and weight loss resulting from chronic medical conditions.

The active ingredient, mirtazapine, addresses reduced appetite and induces significant weight gain in as little as 14 days1. This can allow for a swift response to the initial symptoms, improving condition and wellbeing before you have a definitive diagnosis.

Claire Morgan at Dechra says: ‘Unintended feline weight loss may be associated with serious consequences. Identifying weight loss early, and managing long term, can help improve feline patients’ overall health’.

Mirataz is available in a 5 g tube with innovative child resistant packaging.

For more information about Mirataz visit: www.dechra.co.uk/campaigns/Mirataz

 

Reference

1.Poole M., Quimby J., et al. (2019) A double blind, placebo-controlled, randomized study to evaluate the weight gain drug, mirtazapine transdermal ointment, in cats with unintended weight loss, Journal of Veterinary Pharmacology and Therapeutics, 42(2) : 179-188

Back to news list

Dechra Veterinary Products launches Europe’s first transdermal ointment for body weight gain in cats /Default.aspx?ID=1492&newsid=5428&Action=1&M=NewsV2&PID=7127

Contact

info.uk@dechra.com

News Archive

 
 
 
 
 
 
 
 
 
 
 
 
Website: Co3
  • Terms of Use
  • Privacy Policy
  • Cookie Policy
  • Sitemap
  • Select Dechra business
    • Dechra Pharmaceuticals PLC
    • Dechra Manufacturing

Sign in

Sign in

Help: Forgot password?

 Don't have a Dechra Ireland Website account?

It is free and only takes a few minutes - Sign up today ensuring you are on your local country site first.

Register here